Li Xiao, Xu De Sheng, Li Min, Liu Li, Heng Paul
a Shu-Guang Hospital (affiliated), Shanghai University of Traditional Chinese Medicine , China .
b GEA-NUS Pharmaceutical Processing Research Laboratory, Department of Pharmacy, National University of Singapore , Singapore , and.
Drug Dev Ind Pharm. 2016;42(5):788-95. doi: 10.3109/03639045.2015.1075034. Epub 2015 Aug 17.
This study investigated the applicability of stearic acid as a co-adjuvant in cushioning agent formulated to prevent coat damage when compressing coated pellets. The co-processed and physical blended fillers were prepared by spray drying and physically blending, respectively, with filler ingredients consisting of stearic acid, microcrystalline cellulose, fully gelatinized starch, and corn starch. Pellets containing drug were produced by coating onto non-pariels a drug layer of metformin followed by a sustained-release layer. Drug release from tablets composed of co-processed or physical blended fillers (0, 1, 5, and 10% stearic acid levels) and coated drug containing pellets were analyzed using similarity factor F2. Under the same force and the stearic acid level, co-processed fillers produced pellet containing tablets which showed higher F2 or t50 values and tensile strengths as well as lower yield pressures as compared with tablets containing physical blended fillers. It was shown that the destructive degree of pellet coating was significantly reduced after being co-processed by homogenization and the incorporation of stearic acid in the cushioning agents, as shown by the improved F2 and t50 values. In addition, disintegrate times of tablets containing co-processed agents decreased despite the hydrophobic stearic acid. In conclusion, the inclusion of stearic acid in co-processed cushioning agents was effective at protecting compacted coated pellets from compression-induced damage without compromising disintegratability. The findings could serve as a step towards resolving the technical challenges of balancing the drug release profiles, tablet tensile strength, and disintegration time of compacting coated pellets into multi-particulate-sustained release tablets.
本研究考察了硬脂酸作为一种助辅剂在缓冲剂中的适用性,该缓冲剂用于防止包衣微丸压片时包衣受损。分别通过喷雾干燥和物理混合制备了共处理填充剂和物理混合填充剂,填充剂成分包括硬脂酸、微晶纤维素、全糊化淀粉和玉米淀粉。含药微丸的制备方法是先在空白丸芯上包一层二甲双胍药物层,然后包一层缓释层。使用相似因子F2分析由共处理或物理混合填充剂(硬脂酸水平为0%、1%、5%和10%)组成的片剂以及含包衣药物微丸的药物释放情况。在相同压力和硬脂酸水平下,与含物理混合填充剂的片剂相比,共处理填充剂制备的含微丸片剂显示出更高的F2或t50值以及拉伸强度,同时屈服压力更低。结果表明,通过均质共处理并在缓冲剂中加入硬脂酸后,微丸包衣的破坏程度显著降低,F2和t50值得到改善。此外,尽管硬脂酸具有疏水性,但含共处理剂片剂的崩解时间缩短。总之,在共处理缓冲剂中加入硬脂酸可有效保护压制的包衣微丸免受压片损伤,同时不影响崩解性。这些研究结果有助于解决将包衣微丸压制成多颗粒缓释片剂时在药物释放曲线、片剂拉伸强度和崩解时间之间进行平衡的技术难题。